Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a new cytokine-armored CAR-T cell therapy that helps the immune system better attack aggressive brain tumors in mice while reducing dangerous side effects that have long limited immune-based treatments for glioblastoma, one of the deadliest and most treatment-resistant brain cancers.

The therapy works by reprogramming CAR-T cells to release immune-stimulating proteins, called IL-12 and DR-18, that activate the body’s own immune system, strengthening the overall anti-cancer response. In mouse models, the approach improved tumor control, including against cancers made up of mixed cell populations that often escape therapies.

Researchers also found that pairing the treatment with a second CAR-T strategy targeting VEGF, a protein that drives abnormal blood vessel growth and contributes to swelling in glioblastoma, helped reduce side effects while preserving strong anti-tumor activity.